Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. Eligible patients had platinum-resistant epithelial ovarian...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2021-11, Vol.39 (33), p.3671-3681
Hauptverfasser:	Hamanishi, Junzo, Takeshima, Nobuhiro, Katsumata, Noriyuki, Ushijima, Kimio, Kimura, Tadashi, Takeuchi, Satoshi, Matsumoto, Koji, Ito, Kimihiko, Mandai, Masaki, Nakai, Hidekatsu, Sakuragi, Noriaki, Watari, Hidemichi, Takahashi, Nobutaka, Kato, Hidenori, Hasegawa, Kosei, Yonemori, Kan, Mizuno, Mika, Takehara, Kazuhiro, Niikura, Hitoshi, Sawasaki, Takashi, Nakao, Sari, Saito, Toshiaki, Enomoto, Takayuki, Nagase, Satoru, Suzuki, Nao, Matsumoto, Takashi, Kondo, Eiji, Sonoda, Kenzo, Aihara, Satomi, Aoki, Yoichi, Okamoto, Aikou, Takano, Hirokuni, Kobayashi, Hiroshi, Kato, Hisamori, Terai, Yoshito, Takazawa, Akira, Takahashi, Yusuke, Namba, Yoshinobu, Aoki, Daisuke, Fujiwara, Keiichi, Sugiyama, Toru, Konishi, Ikuo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Drug Resistance, Neoplasm Female Follow-Up Studies Gemcitabine Humans Japan Lymphatic Metastasis Middle Aged Neoplasm Invasiveness Nivolumab - administration & dosage ORIGINAL REPORTS Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Platinum - administration & dosage Polyethylene Glycols - administration & dosage Prognosis Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!